HUT77410A - Rapamicin hidroxi-észterek, eljárás előállításukra, valamint az ezeket tartalmazó gyógyászati készítmények - Google Patents
Rapamicin hidroxi-észterek, eljárás előállításukra, valamint az ezeket tartalmazó gyógyászati készítményekInfo
- Publication number
- HUT77410A HUT77410A HU9602893A HU9602893A HUT77410A HU T77410 A HUT77410 A HU T77410A HU 9602893 A HU9602893 A HU 9602893A HU 9602893 A HU9602893 A HU 9602893A HU T77410 A HUT77410 A HU T77410A
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- hydrogen
- alkynyl
- alkenyl
- tri
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 229960002930 sirolimus Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000000304 alkynyl group Chemical group 0.000 abstract 6
- 150000002431 hydrogen Chemical class 0.000 abstract 6
- 125000000532 dioxanyl group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004276 dioxalanyl group Chemical group 0.000 abstract 2
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Domestic Plumbing Installations (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/229,261 US5362718A (en) | 1994-04-18 | 1994-04-18 | Rapamycin hydroxyesters |
| PCT/US1995/004603 WO1995028406A1 (en) | 1994-04-18 | 1995-04-14 | Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HU9602893D0 HU9602893D0 (en) | 1996-12-30 |
| HUT77410A true HUT77410A (hu) | 1998-04-28 |
| HU225915B1 HU225915B1 (en) | 2007-12-28 |
Family
ID=22860462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9602893A HU225915B1 (en) | 1994-04-18 | 1995-04-14 | Rapamycin hydroxyalkylesters, process for their preparation, their use and pharmaceutical compositions containing them |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US5362718A (hu) |
| EP (3) | EP1760083B1 (hu) |
| JP (1) | JP3725901B2 (hu) |
| KR (1) | KR100330800B1 (hu) |
| CN (1) | CN1059905C (hu) |
| AT (3) | ATE234307T1 (hu) |
| BR (1) | BR9507323A (hu) |
| CA (1) | CA2187024C (hu) |
| CY (2) | CY2378B1 (hu) |
| CZ (1) | CZ284567B6 (hu) |
| DE (3) | DE122008000023I1 (hu) |
| DK (2) | DK0763039T3 (hu) |
| ES (3) | ES2375730T3 (hu) |
| FR (1) | FR08C0018I2 (hu) |
| HK (2) | HK1048816B (hu) |
| HU (1) | HU225915B1 (hu) |
| IL (1) | IL113179A (hu) |
| LU (1) | LU91438I2 (hu) |
| LV (1) | LV13038B (hu) |
| MX (1) | MX9604694A (hu) |
| NL (1) | NL300348I2 (hu) |
| NZ (1) | NZ283988A (hu) |
| PL (1) | PL183178B1 (hu) |
| PT (2) | PT763039E (hu) |
| RU (1) | RU2134267C1 (hu) |
| SI (2) | SI0763039T1 (hu) |
| SK (1) | SK281787B6 (hu) |
| TW (1) | TW275631B (hu) |
| WO (1) | WO1995028406A1 (hu) |
| ZA (1) | ZA953090B (hu) |
Families Citing this family (329)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6281015B1 (en) | 1994-12-16 | 2001-08-28 | Children's Medical Center Corp. | Localized delivery of factors enhancing survival of transplanted cells |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| US5780462A (en) * | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| US5922730A (en) * | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
| US8790391B2 (en) | 1997-04-18 | 2014-07-29 | Cordis Corporation | Methods and devices for delivering therapeutic agents to target vessels |
| US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| US6984635B1 (en) * | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
| US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
| US6331547B1 (en) | 1999-08-18 | 2001-12-18 | American Home Products Corporation | Water soluble SDZ RAD esters |
| US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
| TWI256395B (en) * | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
| US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
| US6670355B2 (en) * | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
| DE60106281T2 (de) | 2000-08-11 | 2005-02-24 | Wyeth | Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms |
| CA2421485A1 (en) | 2000-09-19 | 2002-03-28 | Wyeth | Water soluble rapamycin esters |
| US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
| US20070276473A1 (en) * | 2000-09-29 | 2007-11-29 | Llanos Gerard H | Medical Devices, Drug Coatings and Methods for Maintaining the Drug Coatings Thereon |
| US20060222756A1 (en) * | 2000-09-29 | 2006-10-05 | Cordis Corporation | Medical devices, drug coatings and methods of maintaining the drug coatings thereon |
| ES2275737T3 (es) | 2000-09-29 | 2007-06-16 | Cordis Corporation | Dispositivos medicos revestidos. |
| US6399626B1 (en) * | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
| US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
| TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| NZ526708A (en) | 2000-11-28 | 2005-07-29 | Wyeth Corp | Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP1363627A2 (en) | 2001-02-19 | 2003-11-26 | Novartis AG | Treatment of solid tumours with rapamycin derivatives |
| TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
| TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
| HUP0304093A3 (en) * | 2001-04-06 | 2008-08-28 | Wyeth Corp | Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them |
| ZA200603888B (en) * | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
| UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| ES2246409T3 (es) | 2001-08-22 | 2006-02-16 | Wyeth | 29-enoles de rapamicina. |
| CA2455311A1 (en) * | 2001-08-22 | 2003-03-06 | Wyeth | Rapamycin dialdehydes |
| US6939376B2 (en) | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| US7682387B2 (en) * | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| PL216224B1 (pl) | 2002-02-01 | 2014-03-31 | Ariad Pharmaceuticals | Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie |
| US20040024450A1 (en) * | 2002-04-24 | 2004-02-05 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| DK1505959T3 (da) | 2002-05-16 | 2009-02-23 | Novartis Ag | Anvendelse af EDG-receptorbindingsmidler ved cancer |
| IL165256A0 (en) * | 2002-05-24 | 2005-12-18 | Schering Corp | Neutralizing human anti-igfr antibody |
| AU2003240714B2 (en) | 2002-05-27 | 2006-09-28 | Irm Llc | Bis-aromatic alkanols |
| WO2003106622A2 (en) * | 2002-05-30 | 2003-12-24 | The Children's Hospital Of Philadelphia | Methods for treatment of acute lymphocytic leukemia |
| EP1655372A3 (en) | 2002-07-16 | 2008-01-16 | Biotica Technology Limited | Production of polyketides and other natural products |
| CN100402031C (zh) | 2002-07-30 | 2008-07-16 | 惠氏公司 | 含有瑞帕霉素羟基酯的胃肠外制剂 |
| RU2005106855A (ru) * | 2002-08-12 | 2005-10-10 | Дзе Риджентс оф дзе Юниверсити оф Мичиган (US) | Диагностика и лечение заболеваний, вызываемых дефектами каскада реакций, обусловливающих туберозный склероз |
| AU2003272489B2 (en) * | 2002-09-17 | 2008-11-13 | Wyeth | Granulated formulation of the rapamycin ester CCI779 |
| US20070078513A1 (en) * | 2002-09-18 | 2007-04-05 | Medtronic Vascular, Inc. | Controllable drug releasing gradient coatings for medical devices |
| US20060046979A1 (en) | 2002-09-24 | 2006-03-02 | Foster Carolyn A | Organic compounds |
| AU2003293529A1 (en) | 2002-12-16 | 2004-07-29 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
| ES2395082T3 (es) * | 2003-01-27 | 2013-02-08 | Endocyte, Inc. | Conjugado de folato-vinblastina como medicamento |
| AR042938A1 (es) * | 2003-02-06 | 2005-07-06 | Wyeth Corp | Uso del cci-779 en el tratamiento de la fibrosis hepatica |
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| US20040258662A1 (en) * | 2003-04-22 | 2004-12-23 | Wyeth | Antineoplastic agents |
| CA2522980A1 (en) * | 2003-04-23 | 2004-11-04 | Wyeth Holdings Corporation | Water soluble wortmannin derivatives |
| US7160867B2 (en) * | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| BRPI0410439A (pt) | 2003-05-19 | 2006-06-06 | Irm Llc | compostos e composições imunossupressoras |
| TW200500065A (en) * | 2003-05-21 | 2005-01-01 | Wyeth Corp | Antiarthritic combinations |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| EP1636360A4 (en) * | 2003-06-03 | 2006-11-08 | Cell Genesys Inc | COMPOSITIONS AND METHODS FOR ENHANCED EXPRESSION OF RECOMBINANT POLYPEPTIDES FROM A SINGLE VECTOR USING A PEPTIDE CLEAVAGE SITE |
| BRPI0412659A (pt) * | 2003-07-16 | 2006-09-26 | Wyeth Corp | isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto |
| EP1648454A1 (en) * | 2003-07-25 | 2006-04-26 | Wyeth | Cci-779 lyophilized formulations |
| WO2005016935A2 (en) * | 2003-08-07 | 2005-02-24 | Wyeth | Regioselective synthesis of cci-779 |
| JP2007504226A (ja) * | 2003-09-03 | 2007-03-01 | ワイス | 非晶質状のラパマイシンの３−ヒドロキシ−２−（ヒドロキシメチル）−２−メチルプロピオン酸との４２−エステル、およびそれを含むその医薬組成物 |
| AR046194A1 (es) | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
| US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| AR046639A1 (es) * | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
| UA84903C2 (ru) * | 2004-01-08 | 2008-12-10 | Уайет | Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием |
| AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
| JP2007530654A (ja) * | 2004-03-30 | 2007-11-01 | ファイザー・プロダクツ・インク | シグナル伝達阻害剤の組合せ |
| MXPA06011881A (es) * | 2004-04-14 | 2006-12-14 | Wyeth Corp | Sintesis regioespecifica de derivados de ester-42 de rapamicina. |
| PL1735321T3 (pl) * | 2004-04-14 | 2009-04-30 | Wyeth Corp | Proces wytwarzania 42-estrów rapamycyny i 32-estrów FK-506 z kwasem dikarboksylowym, prekursory koniugatów rapamycyny oraz przeciwciała |
| WO2005100366A1 (en) | 2004-04-14 | 2005-10-27 | Wyeth | Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase |
| US20050239178A1 (en) * | 2004-04-27 | 2005-10-27 | Wyeth | Labeling of rapamycin using rapamycin-specific methylases |
| US20110104186A1 (en) | 2004-06-24 | 2011-05-05 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| WO2006017325A2 (en) * | 2004-07-13 | 2006-02-16 | Cell Genesys, Inc. | Aav vector compositions and methods for enhanced expression of immunoglobulins the same |
| EP1789391B1 (en) | 2004-07-23 | 2017-06-28 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
| PE20060642A1 (es) * | 2004-08-10 | 2006-08-01 | Wyeth Corp | Derivados de 42-ester de rapamicina con acido 2,2-bis(hidoximetil)propionico (cci-779) y metodos para su preparacion |
| GB0417852D0 (en) | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
| US7901451B2 (en) | 2004-09-24 | 2011-03-08 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| EP1804751A2 (en) * | 2004-10-04 | 2007-07-11 | QLT USA, Inc. | Ocular delivery of polymeric delivery formulations |
| US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| CN101048152A (zh) * | 2004-10-28 | 2007-10-03 | 惠氏公司 | mTOR抑制剂在治疗子宫平滑肌瘤中的应用 |
| US20080221660A1 (en) * | 2004-10-28 | 2008-09-11 | Medtronic Vascular, Inc. | Platelet Gel for Treatment of Aneurysms |
| US8021849B2 (en) * | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
| RU2405566C2 (ru) | 2005-02-03 | 2010-12-10 | Дзе Дженерал Хоспитал Корпорейшн | Способ лечения рака, устойчивого к гефитинибу |
| CN101115759A (zh) * | 2005-02-09 | 2008-01-30 | 惠氏公司 | Cci-779多晶形物及其应用 |
| JP2008530145A (ja) * | 2005-02-15 | 2008-08-07 | ワイス | 経口投与可能なｃｃｉ−７７９製剤 |
| GB0503936D0 (en) | 2005-02-25 | 2005-04-06 | San Raffaele Centro Fond | Method |
| AU2006218918A1 (en) * | 2005-03-02 | 2006-09-08 | Wyeth | Purification of rapamycin |
| KR20070107072A (ko) * | 2005-03-02 | 2007-11-06 | 와이어쓰 | 모액으로부터의 ｃｃｉ-７７９의 회수 |
| GB0504544D0 (en) | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| KR20070116868A (ko) | 2005-03-11 | 2007-12-11 | 바이오티카 테크놀로지 리미티드 | ３９데스메톡시라파마이신 및 그 유사체의 의학적 용도 |
| US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| EP1863816B1 (en) * | 2005-03-16 | 2014-06-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
| MX2007012896A (es) * | 2005-04-15 | 2007-12-10 | Schering Corp | Metodos y composiciones para tratamiento o prevencion de cancer. |
| US7189582B2 (en) * | 2005-04-27 | 2007-03-13 | Dade Behring Inc. | Compositions and methods for detection of sirolimus |
| US20070004767A1 (en) * | 2005-06-30 | 2007-01-04 | Gutmann David H | Methods for treating neurofibromatosis 1 |
| US20090062909A1 (en) | 2005-07-15 | 2009-03-05 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
| ES2691646T3 (es) | 2005-07-15 | 2018-11-28 | Micell Technologies, Inc. | Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada |
| US7632509B2 (en) * | 2005-07-19 | 2009-12-15 | Biosante Pharmaceuticals, Inc. | Methods to express recombinant proteins from lentiviral vectors |
| WO2007014278A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| KR101364912B1 (ko) | 2005-08-19 | 2014-02-21 | 엔도사이트, 인코포레이티드 | 복수-약제 리간드 공액체 |
| US8021679B2 (en) | 2005-08-25 | 2011-09-20 | Medtronic Vascular, Inc | Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore |
| AU2006284922B2 (en) | 2005-08-30 | 2012-01-19 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins |
| WO2007056175A2 (en) * | 2005-11-04 | 2007-05-18 | Wyeth | 41-methoxy isotope labeled rapamycin 42-ester |
| PE20070763A1 (es) | 2005-11-04 | 2007-08-08 | Wyeth Corp | COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272 |
| KR20080077619A (ko) * | 2005-12-07 | 2008-08-25 | 와이어쓰 | 라파마이신 42-에스테르 보로네이트로부터 라파마이신42-에스테르를 제조하는 가변적인 방법 |
| AR058283A1 (es) * | 2005-12-07 | 2008-01-30 | Wyeth Corp | Metodos para la preparacion de rapamicina cristalina y para la medicion de la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido |
| BRPI0619493A2 (pt) * | 2005-12-07 | 2016-09-06 | Wyeth Corp | forma cristalina purificada de cci-779, processo para a purificação de cc-779, produto, método para monitorar a cristalização de cci-779, kit, composição farmacêutica, método para o tratamento de câncer, e, uso de um cci-779 purificado |
| RU2473343C2 (ru) * | 2006-02-02 | 2013-01-27 | Новартис Аг | Лечение туберозного склероза |
| US20070203169A1 (en) * | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same |
| KR20080106225A (ko) * | 2006-03-07 | 2008-12-04 | 와이어쓰 | 마크롤라이드 면역억제제의 수용성 폴리에틸렌 글리콜 콘쥬게이트를 제조하는 방법 |
| DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
| US20070292922A1 (en) * | 2006-03-31 | 2007-12-20 | Cell Genesys, Inc. | Regulated expression of recombinant proteins from adeno-associated viral vectors |
| ES2540059T3 (es) | 2006-04-26 | 2015-07-08 | Micell Technologies, Inc. | Recubrimientos que contienen múltiples fármacos |
| US8241619B2 (en) | 2006-05-15 | 2012-08-14 | Medtronic Vascular, Inc. | Hindered amine nitric oxide donating polymers for coating medical devices |
| GB0609962D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
| GB0609963D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
| EP2040758A4 (en) * | 2006-06-30 | 2014-09-17 | Interface Biologics Inc | BIORESPONSIVE POLYMERS |
| US20080207671A1 (en) * | 2006-07-31 | 2008-08-28 | The Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| WO2008016633A2 (en) * | 2006-08-02 | 2008-02-07 | Ariad Gene Therapeutics, Inc. | Combination therapy |
| WO2008022256A2 (en) * | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| US20080051691A1 (en) * | 2006-08-28 | 2008-02-28 | Wyeth | Implantable shunt or catheter enabling gradual delivery of therapeutic agents |
| CN104906087A (zh) | 2006-09-13 | 2015-09-16 | 万能医药公司 | 大环内酯化合物及它们的使用方法 |
| TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
| US20080097591A1 (en) | 2006-10-20 | 2008-04-24 | Biosensors International Group | Drug-delivery endovascular stent and method of use |
| US8067055B2 (en) | 2006-10-20 | 2011-11-29 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method of use |
| US7691402B2 (en) * | 2006-11-06 | 2010-04-06 | Medtronic Vascular, Inc. | Block biodegradable copolymers for medical devices |
| US20080242648A1 (en) * | 2006-11-10 | 2008-10-02 | Syndax Pharmaceuticals, Inc., A California Corporation | COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| EP2090580B1 (en) * | 2006-11-27 | 2014-06-04 | Terumo Kabushiki Kaisha | Process for producing o-alkylated rapamycin derivative, and o-alkylated rapamycin derivative |
| US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
| JP5603598B2 (ja) | 2007-01-08 | 2014-10-08 | ミセル テクノロジーズ、インコーポレイテッド | 生物分解層を有するステント |
| US7753962B2 (en) * | 2007-01-30 | 2010-07-13 | Medtronic Vascular, Inc. | Textured medical devices |
| US20080188461A1 (en) * | 2007-02-01 | 2008-08-07 | Regents Of The University Of Michigan | Compositions and methods for detecting, preventing and treating seizures and seizure related disorders |
| US20100104626A1 (en) | 2007-02-16 | 2010-04-29 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| US7811600B2 (en) * | 2007-03-08 | 2010-10-12 | Medtronic Vascular, Inc. | Nitric oxide donating medical devices and methods of making same |
| US7815927B2 (en) * | 2007-03-08 | 2010-10-19 | Medtronic Vascular, Inc. | Terpolymers for controlled release of bioactive agents from implantable medical devices |
| NZ580132A (en) | 2007-03-14 | 2012-11-30 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins to vitamins |
| US20080245375A1 (en) * | 2007-04-05 | 2008-10-09 | Medtronic Vascular, Inc. | Benign Prostatic Hyperplasia Treatments |
| TW200845960A (en) * | 2007-04-05 | 2008-12-01 | Wyeth Corp | Wortmannin-rapalog conjugate and uses thereof |
| TW200901989A (en) * | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
| US20080306581A1 (en) * | 2007-06-07 | 2008-12-11 | Medtronic Vascular, Inc. | Streamlined Stents |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| EP2176293B1 (en) | 2007-06-25 | 2019-04-03 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
| US8852620B2 (en) * | 2007-07-20 | 2014-10-07 | Medtronic Vascular, Inc. | Medical devices comprising polymeric drug delivery systems with drug solubility gradients |
| US8273828B2 (en) * | 2007-07-24 | 2012-09-25 | Medtronic Vascular, Inc. | Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation |
| US20090043378A1 (en) * | 2007-08-10 | 2009-02-12 | Medtronic Vascular, Inc. | Biocompatible Polymer System for Extended Drug Release |
| US20090076060A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched temsirolimus |
| KR100930167B1 (ko) * | 2007-09-19 | 2009-12-07 | 삼성전기주식회사 | 초광각 광학계 |
| CA2701186C (en) | 2007-10-05 | 2017-09-19 | Interface Biologics Inc. | Oligofluorinated cross-linked polymers and uses thereof |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| ES2623456T3 (es) | 2007-10-19 | 2017-07-11 | Interface Biologics Inc. | Recubrimientos autoeliminantes |
| US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
| WO2009089549A1 (en) * | 2008-01-11 | 2009-07-16 | Massachusetts Eye & Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
| US20090222088A1 (en) * | 2008-02-29 | 2009-09-03 | Medtronic Vascular, Inc. | Secondary Amine Containing Nitric Oxide Releasing Polymer Composition |
| US20100048913A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| US20090232863A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers |
| US20090232868A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Nitric Oxide Releasing Polymer Composition |
| US20090240323A1 (en) * | 2008-03-20 | 2009-09-24 | Medtronic Vascular, Inc. | Controlled Degradation of Magnesium Stents |
| JP5647098B2 (ja) | 2008-03-21 | 2014-12-24 | ザ ユニヴァーシティー オヴ シカゴ | オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療 |
| US20090253733A1 (en) * | 2008-04-02 | 2009-10-08 | Biointeractions, Ltd. | Rapamycin carbonate esters |
| CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
| US20110098241A1 (en) * | 2008-04-14 | 2011-04-28 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
| CA2721832C (en) | 2008-04-17 | 2018-08-07 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
| US20090269480A1 (en) * | 2008-04-24 | 2009-10-29 | Medtronic Vascular, Inc. | Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents |
| US20090297576A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Local Delivery of PAR-1 Antagonists to Treat Vascular Complications |
| US20090299464A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Reducing Bioabsorbtion Time of Polymer Coated Implantable Medical Devices Using Polymer Blends |
| MX365008B (es) | 2008-06-17 | 2019-05-20 | Wyeth Llc | Combinaciones antineoplasticas que contienen hki-272 y vinorelbina. |
| EP3545953A1 (en) | 2008-06-20 | 2019-10-02 | Novartis AG | Paediatric compositions for treating1 multiple sclerosis |
| US9510856B2 (en) | 2008-07-17 | 2016-12-06 | Micell Technologies, Inc. | Drug delivery medical device |
| AU2009270849B2 (en) | 2008-07-17 | 2013-11-21 | Micell Technologies, Inc. | Drug delivery medical device |
| CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| US20100086579A1 (en) * | 2008-10-03 | 2010-04-08 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
| US20100092535A1 (en) * | 2008-10-10 | 2010-04-15 | Medtronic Vascular, Inc. | Nanoporous Drug Delivery System |
| US20100092534A1 (en) * | 2008-10-10 | 2010-04-15 | Medtronic Vascular, Inc. | Combination Local Delivery Using a Stent |
| DK2365802T3 (da) | 2008-11-11 | 2017-11-13 | Univ Texas | Mikrokapsler af rapamycin og anvendelse til behandling af cancer |
| US20100131001A1 (en) * | 2008-11-24 | 2010-05-27 | Medtronic Vascular, Inc. | Targeted Drug Delivery for Aneurysm Treatment |
| US20100131051A1 (en) * | 2008-11-24 | 2010-05-27 | Medtronic Vascular, Inc. | Systems and Methods for Treatment of Aneurysms Using Zinc Chelator(s) |
| US20100152832A1 (en) * | 2008-12-12 | 2010-06-17 | Medtronic Vascular, Inc. | Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta |
| DK2379497T3 (da) | 2008-12-18 | 2013-11-25 | Novartis Ag | Hemifumaratsalt af 1-[4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidin-3-carboxylsyre |
| WO2010071794A1 (en) | 2008-12-18 | 2010-06-24 | Novartis Ag | New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic |
| RU2011129229A (ru) | 2008-12-18 | 2013-01-27 | Новартис Аг | Новые соли |
| US8158187B2 (en) * | 2008-12-19 | 2012-04-17 | Medtronic Vascular, Inc. | Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices |
| US20100198338A1 (en) * | 2009-01-30 | 2010-08-05 | Medtronic Vascular, Inc., A Delaware Corporation | Hydrogen Sulfide Donating Polymers |
| EP3023433A1 (en) | 2009-02-05 | 2016-05-25 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| US20100227799A1 (en) * | 2009-03-09 | 2010-09-09 | Medtronic Vascular, Inc. | Simultaneous photodynamic therapy and photo induced polymerization |
| CA2757276C (en) | 2009-04-01 | 2017-06-06 | Micell Technologies, Inc. | Coated stents |
| US8236341B2 (en) * | 2009-04-02 | 2012-08-07 | Medtronic Vascular, Inc. | Poly(tetrafluoroethylene) polymer with nitric oxide donating surface |
| US20100256728A1 (en) * | 2009-04-07 | 2010-10-07 | Medtronic Vascular, Inc. | Semi-Permiable Biodegradable Stent Graft and Uses Thereof |
| US8709465B2 (en) * | 2009-04-13 | 2014-04-29 | Medtronic Vascular, Inc. | Diazeniumdiolated phosphorylcholine polymers for nitric oxide release |
| US8852590B2 (en) | 2009-04-16 | 2014-10-07 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| WO2010121187A2 (en) | 2009-04-17 | 2010-10-21 | Micell Techologies, Inc. | Stents having controlled elution |
| US8716307B2 (en) | 2009-05-13 | 2014-05-06 | The Trustees Of The University Of Pennsylvania | Combination antineoplastic therapy |
| ES2586837T3 (es) | 2009-08-03 | 2016-10-19 | University Of Miami | Método para la expansión in vivo de linfocitos T reguladores |
| EP2480557A2 (en) | 2009-09-25 | 2012-08-01 | Cadila Healthcare Limited | Process for the preparation of rapamycin derivatives |
| EP2491032B1 (en) | 2009-10-23 | 2014-04-16 | Eli Lilly and Company | Akt inhibitors |
| EP2493460A4 (en) | 2009-10-30 | 2013-04-24 | Ariad Pharma Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| US20170079962A1 (en) | 2009-11-11 | 2017-03-23 | Rapamycin Holdings, Llc | Oral Rapamycin Preparation and Use for Stomatitus |
| CN102933658A (zh) | 2009-12-18 | 2013-02-13 | 界面生物公司 | 从自组装涂层局部递送药物 |
| US8182830B2 (en) * | 2010-01-05 | 2012-05-22 | Medtronic Vascular, Inc. | Hydrogen sulfide generating polymers |
| WO2011092564A2 (en) | 2010-01-28 | 2011-08-04 | Fresenius Kabi Oncology Ltd | Process for the preparation of temsirolimus and its intermediates |
| US11369498B2 (en) | 2010-02-02 | 2022-06-28 | MT Acquisition Holdings LLC | Stent and stent delivery system with improved deliverability |
| JP2013521002A (ja) | 2010-03-05 | 2013-06-10 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 誘導樹状細胞組成物及びその使用 |
| EP2560576B1 (en) | 2010-04-22 | 2018-07-18 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
| EP2563391B1 (en) | 2010-04-27 | 2020-08-26 | Roche Glycart AG | Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
| WO2011151704A2 (en) | 2010-06-02 | 2011-12-08 | Fresenius Kabi Oncology Ltd. | Stable pharmaceutical compositions of rapamycin esters |
| US20130172853A1 (en) | 2010-07-16 | 2013-07-04 | Micell Technologies, Inc. | Drug delivery medical device |
| WO2012017449A1 (en) * | 2010-08-04 | 2012-02-09 | Meril Life Sciences Pvt. Ltd | Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties" |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012068487A1 (en) | 2010-11-18 | 2012-05-24 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
| CA2817564A1 (en) | 2010-11-18 | 2012-05-24 | Ronald K. Blackman | Preselection of subjects for therapeutic treatment based on hypoxic status |
| ES2423798T3 (es) | 2010-11-19 | 2013-09-24 | Universitätsklinikum Freiburg | Hidrogeles de PEG disolubles sensibles a estímulos biofuncionalizados |
| CN102020662B (zh) * | 2011-01-07 | 2013-02-13 | 天津市炜杰科技有限公司 | 一种驮瑞塞尔制备方法 |
| EP2675451B9 (en) | 2011-02-18 | 2017-07-26 | Novartis Pharma AG | mTOR/JAK INHIBITOR COMBINATION THERAPY |
| US9051336B2 (en) | 2011-04-01 | 2015-06-09 | Sandoz | Regioselective acylation of rapamycin at the C-42 position |
| AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| JP2014516075A (ja) | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | 癌治療のためのメタロセン化合物の使用 |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| CA2841360A1 (en) | 2011-07-15 | 2013-01-24 | Micell Technologies, Inc. | Drug delivery medical device |
| WO2013013708A1 (en) | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Treatment of acute rejection in renal transplant |
| US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
| CN102424829B (zh) * | 2011-10-26 | 2013-10-16 | 苏州汉酶生物技术有限公司 | 一种酶催化合成坦西莫司的方法 |
| US9642918B2 (en) | 2011-12-16 | 2017-05-09 | Pfizer Inc. | Combination of inotuzumab ozogamicin and torisel for the treatment of cancer |
| GB201122305D0 (en) | 2011-12-23 | 2012-02-01 | Biotica Tech Ltd | Novel compound |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| CN102796115B (zh) * | 2012-05-25 | 2015-07-15 | 上海现代制药股份有限公司 | 一种坦西莫司的制备方法 |
| CN103705925B (zh) | 2012-09-29 | 2018-03-30 | 段磊 | 抑制PI3K/AKT/mTOR信号通路的药物组合 |
| US9750728B2 (en) | 2012-09-29 | 2017-09-05 | Targeted Therapeutics, Llc | Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway |
| WO2014059295A1 (en) | 2012-10-12 | 2014-04-17 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
| KR20150070318A (ko) | 2012-10-16 | 2015-06-24 | 엔도사이트, 인코포레이티드 | 비천연 아미노산을 함유하는 약물 전달 컨쥬게이트 및 사용 방법 |
| US20150258127A1 (en) | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| CA2897826C (en) | 2013-01-09 | 2022-09-27 | Taylor H. Schreiber | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
| CN110423282B (zh) | 2013-02-15 | 2023-09-08 | 加利福尼亚大学董事会 | 嵌合抗原受体及其使用方法 |
| JP6330024B2 (ja) | 2013-03-12 | 2018-05-23 | マイセル・テクノロジーズ，インコーポレイテッド | 生体吸収性バイオメディカルインプラント |
| EP2968281B1 (en) | 2013-03-13 | 2020-08-05 | The Board of Regents of The University of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| KR20150127720A (ko) | 2013-03-14 | 2015-11-17 | 유니버시티 오브 매릴랜드, 발티모어 | 안드로겐 수용체 하향 조절제 및 그의 용도 |
| WO2014182635A1 (en) | 2013-05-08 | 2014-11-13 | Baldwin Megan E | Biomarkers for age-related macular degeneration (amd) |
| WO2014186532A1 (en) | 2013-05-15 | 2014-11-20 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
| CN103421023B (zh) * | 2013-07-30 | 2015-09-23 | 福建省微生物研究所 | 一种替西罗莫司的合成工艺 |
| BR112016002970A2 (pt) | 2013-08-12 | 2017-09-12 | Tokai Pharmaceuticals Inc | biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio |
| WO2015073644A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Ag | Mtor inhibitors for enhancing the immune response |
| EP2878312A1 (en) | 2013-12-02 | 2015-06-03 | Albert-Ludwigs-Universität Freiburg | Reversible PEGylation of nanocarriers |
| CA2931684C (en) | 2013-12-19 | 2024-02-20 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| CA2933908C (en) | 2013-12-31 | 2024-01-30 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| WO2015108912A1 (en) | 2014-01-16 | 2015-07-23 | MUSC Foundation for Research and Development | Targeted nanocarriers for the administration of immunosuppressive agents |
| WO2015142661A1 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| CA2943609A1 (en) | 2014-03-27 | 2015-10-01 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
| KR102487608B1 (ko) | 2014-04-07 | 2023-01-12 | 노파르티스 아게 | 항-cd19 키메라 항원 수용체를 사용한 암의 치료 |
| CN106659758A (zh) | 2014-06-02 | 2017-05-10 | 儿童医疗中心有限公司 | 用于免疫调节的组合物和方法 |
| CN112481283A (zh) | 2014-07-21 | 2021-03-12 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
| WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| CN104086564B (zh) * | 2014-07-30 | 2019-02-05 | 江苏奥赛康药业股份有限公司 | 一种高纯度坦罗莫司的制备方法 |
| ES2781175T3 (es) | 2014-07-31 | 2020-08-31 | Novartis Ag | Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico |
| US10851149B2 (en) | 2014-08-14 | 2020-12-01 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using GFR α-4 chimeric antigen receptor |
| JP7084138B2 (ja) | 2014-08-19 | 2022-06-14 | ノバルティス アーゲー | 癌処置に使用するための抗ｃｄ１２３キメラ抗原受容体（ｃａｒ） |
| WO2016040806A1 (en) | 2014-09-11 | 2016-03-17 | The Regents Of The University Of California | mTORC1 INHIBITORS |
| CN114621969A (zh) | 2014-09-17 | 2022-06-14 | 诺华股份有限公司 | 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞 |
| EP2997977A1 (en) | 2014-09-19 | 2016-03-23 | Fundación de la Comunidad Valenciana Centro de Investigación Principe Felipe | Specific mtor inhibitors in the treatment of x-linked adrenoleukodystrophy |
| AU2015330898B2 (en) | 2014-10-08 | 2022-03-10 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| US20190054117A1 (en) | 2014-12-19 | 2019-02-21 | Novartis Ag | Dimerization switches and uses thereof |
| US10377818B2 (en) | 2015-01-30 | 2019-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating glioma |
| ES2876974T3 (es) | 2015-04-07 | 2021-11-15 | Novartis Ag | Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina |
| EP4234685A3 (en) | 2015-04-17 | 2023-09-06 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| JP6857141B2 (ja) | 2015-05-20 | 2021-04-14 | ノバルティス アーゲー | エベロリムスとダクトリシブとの薬学的組合せ |
| WO2016196655A1 (en) | 2015-06-03 | 2016-12-08 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
| WO2017029391A1 (en) | 2015-08-20 | 2017-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating cancer |
| AU2016352806A1 (en) | 2015-11-11 | 2018-05-10 | Novartis Ag | Uses of myostatin antagonists, combinations containing them and uses thereof |
| US10765665B2 (en) | 2015-11-24 | 2020-09-08 | Melin Jeffrey | Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases |
| WO2020047527A2 (en) | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
| CA3031542A1 (en) | 2016-07-20 | 2018-01-25 | University Of Utah Research Foundation | Cd229 car t cells and methods of use thereof |
| CN109996549A (zh) | 2016-09-22 | 2019-07-09 | 墨卡托医疗系统公司 | 使用坦罗莫司治疗再狭窄 |
| AR110676A1 (es) | 2016-10-07 | 2019-04-24 | Novartis Ag | Tratamiento del cáncer utilizando receptores de antígenos quiméricos |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| CN110603038A (zh) | 2017-02-10 | 2019-12-20 | 塔姆山治疗公司 | 雷帕霉素类似物 |
| CA3054064A1 (en) | 2017-03-03 | 2018-09-07 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| WO2018213352A1 (en) | 2017-05-15 | 2018-11-22 | C.R. Bard, Inc. | Medical device with drug-eluting coating and intermediate layer |
| CN108948045A (zh) * | 2017-05-20 | 2018-12-07 | 鲁南制药集团股份有限公司 | 一种替西罗莫司的制备方法 |
| WO2018218182A1 (en) | 2017-05-26 | 2018-11-29 | Mercator Medsystems, Inc. | Combination therapy for treatment of restenosis |
| WO2019002168A1 (en) | 2017-06-26 | 2019-01-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING OLMSTED SYNDROME |
| US20210147801A1 (en) | 2017-07-13 | 2021-05-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/- tregs |
| AR112834A1 (es) | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| CN110382019B (zh) | 2018-03-14 | 2020-08-25 | 墨卡托医疗系统公司 | 用于局部药物递送的医疗器械和医疗方法 |
| EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
| AU2019262979B2 (en) | 2018-05-01 | 2023-07-06 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
| WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| CA3098692A1 (en) | 2018-05-01 | 2019-11-07 | Revolution Medicines, Inc. | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors |
| CN112638436A (zh) | 2018-05-22 | 2021-04-09 | 界面生物公司 | 用于将药物递送至血管壁的组合物和方法 |
| EP3826649A4 (en) | 2018-07-23 | 2022-07-20 | Enclear Therapies, Inc. | METHODS OF TREATMENT OF NEUROLOGICAL DISORDERS |
| WO2020023418A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
| WO2020053125A1 (en) | 2018-09-10 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of neurofibromatosis |
| JP2022512594A (ja) | 2018-10-05 | 2022-02-07 | ザンクト アンナ キンダークレプスフォルシュング | キメラ抗原受容体（ｃａｒ）の群 |
| EP3632461A1 (en) | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| EP3632460A1 (en) | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| JP2022504191A (ja) | 2018-10-05 | 2022-01-13 | ザンクト アンナ キンダークレプスフォルシュング | キメラ抗原受容体（ｃａｒ）群 |
| WO2020101675A1 (en) | 2018-11-14 | 2020-05-22 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
| SG11202106635WA (en) | 2018-12-21 | 2021-07-29 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate and kinase inhibitor |
| CN113939324A (zh) | 2019-04-08 | 2022-01-14 | 巴德外周血管股份有限公司 | 在经改性装置表面上具有药物洗脱涂层的医疗装置 |
| KR20220011123A (ko) | 2019-04-11 | 2022-01-27 | 엔클리어 테라피스, 인크. | 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템 |
| CN113372359A (zh) * | 2020-03-10 | 2021-09-10 | 鲁南制药集团股份有限公司 | 一种坦西莫司的制备方法 |
| JP2023550544A (ja) | 2020-11-03 | 2023-12-01 | アールディスカバリー エルエルシー | がんおよびファゴサイトーシス不全に関連する疾患の処置のための療法 |
| CA3223081A1 (en) | 2021-07-15 | 2023-01-19 | Samir Mitragotri | Compositions and methods relating to cells with adhered particles |
| WO2024008799A1 (en) | 2022-07-06 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of proliferative glomerulonephritis |
| WO2024028433A1 (en) | 2022-08-04 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
| WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) * | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| US4316885A (en) * | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4375464A (en) * | 1981-11-19 | 1983-03-01 | Ayerst, Mckenna & Harrison Inc. | Antibiotic AY24,668 and process of preparation |
| US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| US5023264A (en) * | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
| US5023263A (en) * | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
| US5023262A (en) * | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| US5221670A (en) * | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
| PT98990A (pt) * | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
| US5130307A (en) * | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
| US5233036A (en) * | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
| US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| US5080899A (en) * | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
| US5120842A (en) * | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| IL101353A0 (en) * | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
| US5100883A (en) * | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| JPH05112573A (ja) | 1991-04-17 | 1993-05-07 | American Home Prod Corp | ラパマイシンのカルバミン酸エステル類 |
| US5118678A (en) * | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5194447A (en) * | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
| US5091389A (en) * | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
| US5138051A (en) * | 1991-08-07 | 1992-08-11 | American Home Products Corporation | Rapamycin analogs as immunosuppressants and antifungals |
| US5102876A (en) * | 1991-05-07 | 1992-04-07 | American Home Products Corporation | Reduction products of rapamycin |
| US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| DE69209183T2 (de) | 1991-06-18 | 1996-08-08 | American Home Prod | Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen |
| ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US5169851A (en) * | 1991-08-07 | 1992-12-08 | American Home Products Corporation | Rapamycin analog as immunosuppressants and antifungals |
| US5286730A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5286731A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
| US5151413A (en) * | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| US5177203A (en) * | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5262423A (en) * | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
| US5260300A (en) * | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
| US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
| TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
-
1994
- 1994-04-18 US US08/229,261 patent/US5362718A/en not_active Ceased
- 1994-11-08 TW TW083110308A patent/TW275631B/zh not_active IP Right Cessation
-
1995
- 1995-03-29 IL IL113179A patent/IL113179A/en not_active IP Right Cessation
- 1995-04-13 ZA ZA953090A patent/ZA953090B/xx unknown
- 1995-04-14 NZ NZ283988A patent/NZ283988A/en not_active IP Right Cessation
- 1995-04-14 EP EP06026307A patent/EP1760083B1/en not_active Expired - Lifetime
- 1995-04-14 PT PT95915671T patent/PT763039E/pt unknown
- 1995-04-14 DE DE122008000023C patent/DE122008000023I1/de active Pending
- 1995-04-14 CN CN95193325A patent/CN1059905C/zh not_active Expired - Lifetime
- 1995-04-14 MX MX9604694A patent/MX9604694A/es unknown
- 1995-04-14 CZ CZ963052A patent/CZ284567B6/cs not_active IP Right Cessation
- 1995-04-14 PL PL95316948A patent/PL183178B1/pl unknown
- 1995-04-14 PT PT02014322T patent/PT1266899E/pt unknown
- 1995-04-14 AT AT95915671T patent/ATE234307T1/de active
- 1995-04-14 EP EP95915671.2A patent/EP0763039B3/en not_active Expired - Lifetime
- 1995-04-14 EP EP02014322A patent/EP1266899B1/en not_active Expired - Lifetime
- 1995-04-14 KR KR1019960705839A patent/KR100330800B1/ko active IP Right Grant
- 1995-04-14 WO PCT/US1995/004603 patent/WO1995028406A1/en active IP Right Grant
- 1995-04-14 JP JP52710595A patent/JP3725901B2/ja not_active Expired - Lifetime
- 1995-04-14 ES ES06026307T patent/ES2375730T3/es not_active Expired - Lifetime
- 1995-04-14 ES ES02014322T patent/ES2277975T3/es not_active Expired - Lifetime
- 1995-04-14 DK DK95915671T patent/DK0763039T3/da active
- 1995-04-14 RU RU96122172A patent/RU2134267C1/ru active
- 1995-04-14 CA CA002187024A patent/CA2187024C/en not_active Expired - Lifetime
- 1995-04-14 DK DK02014322T patent/DK1266899T3/da active
- 1995-04-14 ES ES95915671.2T patent/ES2191704T7/es active Active
- 1995-04-14 AT AT06026307T patent/ATE537176T1/de active
- 1995-04-14 SK SK1330-96A patent/SK281787B6/sk not_active IP Right Cessation
- 1995-04-14 DE DE69529897.6T patent/DE69529897T3/de not_active Expired - Lifetime
- 1995-04-14 AT AT02014322T patent/ATE350384T1/de active
- 1995-04-14 SI SI9530648T patent/SI0763039T1/xx unknown
- 1995-04-14 BR BR9507323A patent/BR9507323A/pt active IP Right Grant
- 1995-04-14 SI SI9530730T patent/SI1266899T1/sl unknown
- 1995-04-14 DE DE69535363T patent/DE69535363T2/de not_active Expired - Lifetime
- 1995-04-14 HU HU9602893A patent/HU225915B1/hu active Protection Beyond IP Right Term
-
1998
- 1998-11-24 HK HK03101048.7A patent/HK1048816B/zh not_active IP Right Cessation
- 1998-11-24 HK HK98112275A patent/HK1011352A1/xx not_active IP Right Cessation
-
2003
- 2003-05-13 LV LVP-03-47A patent/LV13038B/en unknown
- 2003-09-12 CY CY0300065A patent/CY2378B1/xx unknown
-
2008
- 2008-05-15 NL NL300348C patent/NL300348I2/nl unknown
- 2008-05-15 LU LU91438C patent/LU91438I2/fr unknown
- 2008-05-16 FR FR08C0018C patent/FR08C0018I2/fr active Active
- 2008-05-19 CY CY200800012C patent/CY2008012I2/el unknown
-
2013
- 2013-06-28 US US13/931,400 patent/USRE44768E1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU9602893D0 (en) | Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them | |
| IL103558A0 (en) | Tri-substituted tetrahydrofuran antifungals | |
| AU3822193A (en) | Azole compounds, their production and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DGB9 | Succession in title of applicant |
Owner name: WYETH, US |
|
| AA1S | Information on application for a supplementary protection certificate |
Free format text: PRODUCT NAME: TEMISROLIMUS AND IT'S PHARMACEUTICALLY ACCEPTABLE SALTS; REG. NO/DATE: EU/1/07/424/001 20071119 Spc suppl protection certif: S0800005 Filing date: 20080516 Expiry date: 20150414 Free format text: PRODUCT NAME: TEMSIRDIMUS/TORISEL; NATIONAL REGISTRATION NO/DATE: EU/1/07/424/001*2007.11.19 Spc suppl protection certif: S0800005 Filing date: 20080516 Expiry date: 20150414 |
|
| FG4S | Grant of supplementary protection certificate |
Free format text: PRODUCT NAME: TEMISROLIMUS AND IT'S PHARMACEUTICALLY ACCEPTABLE SALTS; REG. NO/DATE: EU/1/07/424/001 20071119 Spc suppl protection certif: S0800005 Filing date: 20080516 Expiry date: 20150414 Extension date: 20200414 |